Open an account

Clearside Biomedical

CLSD · NASDAQ

Price unavailable right now.

No price history for this range.

About CLSD

Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Employees
32
Headquarters
Alpharetta, Georgia
Listed
Jun 2, 2016
Sector
Health Care
Industry
Pharmaceuticals
Website
clearsidebio.com

CLSD key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 4 analystsAvg $84.15
Low
$75.75
High
$94.50

CLSD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 20.3% on average.

  1. Q4 FY23: reported -$1.20 per share against an estimate of -$1.34
  2. Q1 FY24: reported -$2.25 per share against an estimate of -$2.11
  3. Q2 FY24: reported -$1.50 per share against an estimate of -$2.07
  4. Q3 FY24: reported -$1.50 per share against an estimate of -$1.90
  5. Q4 FY24: reported -$1.50 per share against an estimate of -$1.49
  6. Q1 FY25: reported -$1.65 per share against an estimate of -$1.66
  7. Q2 FY25: reported -$0.90 per share against an estimate of -$1.55
  8. Q3 FY25: reported -$1.14 per share against an estimate of -$0.5355

CLSD news

  • Avi Kapoor

    Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Anthony Noto

    Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • A Peek at Clearside Biomedical's Future Earnings

  • Exploring Clearside Biomedical's Earnings Expectations

Similar companies

Companies in the same industry as Clearside Biomedical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.